CA2871151C - Treatment of addiction and impulse-control disorders using pde7 inhibitors - Google Patents

Treatment of addiction and impulse-control disorders using pde7 inhibitors Download PDF

Info

Publication number
CA2871151C
CA2871151C CA2871151A CA2871151A CA2871151C CA 2871151 C CA2871151 C CA 2871151C CA 2871151 A CA2871151 A CA 2871151A CA 2871151 A CA2871151 A CA 2871151A CA 2871151 C CA2871151 C CA 2871151C
Authority
CA
Canada
Prior art keywords
alkyl
aryl
substituted
optionally substituted
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2871151A
Other languages
English (en)
French (fr)
Other versions
CA2871151A1 (en
Inventor
Gregory A. Demopulos
George A. Gaitanaris
Roberto Ciccocioppo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Omeros Corp
Original Assignee
Omeros Medical Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/835,607 external-priority patent/US9220715B2/en
Application filed by Omeros Medical Systems Inc filed Critical Omeros Medical Systems Inc
Publication of CA2871151A1 publication Critical patent/CA2871151A1/en
Application granted granted Critical
Publication of CA2871151C publication Critical patent/CA2871151C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Addiction (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2871151A 2012-05-07 2013-05-07 Treatment of addiction and impulse-control disorders using pde7 inhibitors Active CA2871151C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261643611P 2012-05-07 2012-05-07
US61/643,611 2012-05-07
US13/835,607 US9220715B2 (en) 2010-11-08 2013-03-15 Treatment of addiction and impulse-control disorders using PDE7 inhibitors
US13/835,607 2013-03-15
PCT/US2013/039866 WO2013176877A2 (en) 2012-05-07 2013-05-07 Treatment of addiction and impulse-control disorders using pde7 inhibitors

Publications (2)

Publication Number Publication Date
CA2871151A1 CA2871151A1 (en) 2013-11-28
CA2871151C true CA2871151C (en) 2019-03-26

Family

ID=49624481

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2871151A Active CA2871151C (en) 2012-05-07 2013-05-07 Treatment of addiction and impulse-control disorders using pde7 inhibitors

Country Status (10)

Country Link
EP (1) EP2846805B1 (enExample)
JP (1) JP2015521177A (enExample)
CN (3) CN104768556A (enExample)
AU (1) AU2013266793B2 (enExample)
CA (1) CA2871151C (enExample)
IN (1) IN2014DN10404A (enExample)
PL (1) PL2846805T3 (enExample)
RS (1) RS58381B1 (enExample)
SI (1) SI2846805T1 (enExample)
WO (1) WO2013176877A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102385359B1 (ko) 2010-11-08 2022-04-11 오메로스 코포레이션 Pde7 억제제를 사용한 중독 및 충동-조절 장애의 치료
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
MX2019002281A (es) * 2016-08-26 2019-06-20 Mitsubishi Tanabe Pharma Corp Compuesto heterociclico nitrogenado biciclico.
US20250367212A1 (en) * 2022-06-15 2025-12-04 Shinichi Matsumoto Pharmacotherapy for obsessive-compulsive disorder targeting dopamine d1 signal in striatal striosomes
CA3264513A1 (en) * 2022-08-18 2024-02-22 Mitodicure Gmbh USE OF SUBSTITUTED BENZOFURAN AND BENZOXAZOLE COMPOUNDS FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERCISE INTOLERANCE

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2433943T3 (da) * 2004-07-01 2013-12-16 Daiichi Sankyo Co Ltd Mellemprodukter til thienopyrazol-derivater med PDE7-inhibitorisk aktivitet
US20060183763A1 (en) * 2004-12-31 2006-08-17 Pfizer Inc Novel pyrrolidyl derivatives of heteroaromatic compounds
EP1928438B1 (en) * 2005-09-26 2013-03-20 Avigen, Inc. Use of ibudilast for treating drug addictions
US8637528B2 (en) * 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
MX2009010450A (es) * 2007-03-27 2009-11-23 Omeros Corp El uso de inhibidores de la fosfodiesterasa 7 para el tratamiento transtornos del movimiento.
WO2008128126A1 (en) * 2007-04-11 2008-10-23 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
FR2943673B1 (fr) * 2009-03-27 2013-03-29 Sanofi Aventis Applications therapeutiques de derives de quinazolinedione
FR2944282B1 (fr) * 2009-04-09 2013-05-03 Sanofi Aventis Derives de quinazolinedione, leur preparation et leurs diverses applications therapeutiques
KR102385359B1 (ko) * 2010-11-08 2022-04-11 오메로스 코포레이션 Pde7 억제제를 사용한 중독 및 충동-조절 장애의 치료

Also Published As

Publication number Publication date
RS58381B1 (sr) 2019-04-30
AU2013266793A1 (en) 2014-11-27
EP2846805A2 (en) 2015-03-18
AU2013266793B2 (en) 2016-08-04
CA2871151A1 (en) 2013-11-28
SI2846805T1 (sl) 2019-04-30
CN112168972A (zh) 2021-01-05
WO2013176877A2 (en) 2013-11-28
PL2846805T3 (pl) 2019-05-31
EP2846805A4 (en) 2016-08-10
WO2013176877A3 (en) 2015-06-18
IN2014DN10404A (enExample) 2015-08-14
EP2846805B1 (en) 2018-11-21
CN104768556A (zh) 2015-07-08
CN114984229A (zh) 2022-09-02
JP2015521177A (ja) 2015-07-27

Similar Documents

Publication Publication Date Title
CA2817071C (en) Treatment of addiction and impulse-control disorders using pde7 inhibitors
US11464785B2 (en) Treatment of addiction and impulse-control disorders using PDE7 inhibitors
AU2013266793B2 (en) Treatment of addiction and impulse-control disorders using PDE7 inhibitors
DK2846805T3 (en) TREATMENT OF DEPENDENCE AND IMPULSE CONTROL DISORDERS USING PDE7 INHIBITORS
US20230110784A1 (en) Treatment of addiction and impulse-control disorders using pde7 inhibitors
AU2013201989B2 (en) Treatment of addiction and impulse-control disorders using PDE7 inhibitors
HK40103491A (en) Treatment of addiction and impulse-control disorders using pde7 inhibitors
HK1208373B (en) Treatment of addiction and impulse-control disorders using pde7 inhibitors

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20141021

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250502

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250502